We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid DNA Flow Technology Platform Detects Tick-Borne Bacterial Pathogens

By LabMedica International staff writers
Posted on 13 Nov 2019
Print article
Image: Simultaneous detection of Anaplasma spp., Bartonella spp., Borrelia spp., Coxiella burnetii, Francisella spp., and Rickettsia spp. on a tick-borne bacteria flow chip (TBFC) kit (Photo courtesy of Rutgers University).
Image: Simultaneous detection of Anaplasma spp., Bartonella spp., Borrelia spp., Coxiella burnetii, Francisella spp., and Rickettsia spp. on a tick-borne bacteria flow chip (TBFC) kit (Photo courtesy of Rutgers University).
Ticks are the most important vectors for infectious diseases in the northern hemisphere and second only after mosquitos worldwide. As a result, there is an increasing public health interest in tick-borne pathogens.

Ticks can transmit diseases such as Lyme disease, human granulocytic anaplasmosis, and spotted fever rickettsioses, among others. Therefore, there is a growing need to develop better and faster diagnostic tools that can detect zoonotic human pathogens in clinical samples.

Medical Infectious Disease Scientists from Rutgers University (New Brunswick, NJ, USA) and their international colleagues collected samples from 212 patients who presented a broad range of clinical signs/symptoms consistent with multisystem disorders that could be suggestive of an infection caused by any of the pathogens included in the panel of the tick-borne bacteria flow chip (TBFC) kit. Human DNA was used to spike positive controls came from cerebrospinal fluid (CSF) or biopsies from patients who tested negative to the pathogens included in the testing of the TBFC kit.

The TBFC is intended for the simultaneous qualitative detection of DNA from seven different genera of tick-borne bacteria, Anaplasma, Ehrlichia, Borrelia, Bartonella, Coxiella, Rickettsia, and Francisella, using a multiplex PCR followed by reverse dot blot automatic hybridization into a macroarray CHIP based on DNA-Flow Technology (hybriSpot). The kit offers the amplification of bacterial DNA by two multiplex polymerase chain reactions (PCRs) containing all primers for the specific amplification of the seven bacteria genera and two sets of primers for the amplification of two internal controls.

The scientists reported that the sensitivity of the TBFC was tested for each pathogen independently in the presence of human DNA. Despite human co-infections with tick-borne pathogens being rare, one of the strengths of the TBFC is that it can detect them. To prove that the TBFC detects co-infections, they included positive controls (103–104 plasmid copy/genome equivalents, PC/GE) for each pathogen. The results confirmed that the TBFC could detect all the pathogens simultaneously without compromising its sensitivity.

The TBFC platform offers four significant advantages. First, it is rapid and automatized, significantly shortening the time for the diagnosis of tick-borne pathogens. The TBFC kit gives results in 3.5 hours, while the in-house PCR-reverse line blot takes 8.5 hours for one pathogen. Second, it allows the simultaneous detection of multiple pathogens, which represents an excellent advantage for diseases that display similar symptoms early on. Third, the TBFC can analyze a wide variety of clinical samples with high sensitivity and specificity. Fourth, it is a valuable alternative to serology for early diagnosis.

The authors concluded that the TBFC kit is a rapid and highly sensitive and specific diagnostic tool, capable of simultaneously screening multiple bacterial pathogens. The study was published on October 22, 2019 in the journal Vector-Borne and Zoonotic Diseases.

Related Links:
Rutgers University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.